A month after halting dosing in two of the three treatment arms of a phase 2 trial of its pulmonary arterial hypertension ...

Keros Therapeutics has halted the dosing of its treatment for pulmonary hypertension due to adverse health effects discovered during trials. The clinical-stage biopharmaceutical company said Wednesday ...

Cibotercept is under clinical development by Keros Therapeutics and currently in Phase II for Pulmonary Arterial Hypertension.

Shares in Keros Therapeutics fell sharply Wednesday morning after it said it halted trials of its treatment for pulmonary hypertension after finding adverse health effects in patients trialing the ...

has granted Orphan Drug Designation to ALG-801 for the treatment of pulmonary arterial hypertension (PAH), a rare, serious, and life-threatening condition characterized by high blood pressure in the ...

has granted Orphan Drug Designation to ALG-801 for the treatment of pulmonary arterial hypertension (PAH), a rare, serious, and life-threatening condition characterized by high blood pressure in ...

Anticipated growth for ‘Saudi Arabia Pulmonary Arterial Hypertension Market’ is significant from 2024 to 2032. The market showed steady growth in 2024 and is expected to continue rising due to ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved the medicine sotatercept (Winrevair) to treat pulmonary arterial hypertension (PAH). Sotatercept is used, in combination ...

One of the most straightforward signs that you do not have hypertension is consistently normal blood pressure readings. A ...

notes. After a lifetime of sports and teaching physical education, John was blindsided 16 years ago to learn he had Pulmonary Arterial Hypertension, or PAH. It appeared suddenly after a heart ...

MSD has received the UK Medicines and Healthcare products Regulatory Agency (MHRA) approval for sotatercept, marketed as ...